LPLD Alliance works to improve the lives of people affected by Familial Chylomicronaemia Syndrome (FCS). FCS is an ultra-rare condition affecting 1 to 2:1,000,000 people.
People with FCS are unable to digest most fats as their lipoprotein lipase, the enzyme which breaks down fat, is either absent, limited or defective. As a result, fat stays within the blood stream in the form of particles called chylomicrons giving the blood its classic creamy-white appearance and causing symptoms including recurrent and severe abdominal pain and life-threatening pancreatitis.
The damage caused to the pancreas by FCS also significantly increases the risk of developing type 2 diabetes.
Currently the only treatment for the condition is a radical reduction of fat in the diet to under 20g fat daily which is very difficult to achieve, and places a huge burden of the lives of patients and those close to them.